Skip to main content
OpenTrials
Completed

NCT Number: NCT03669497

Hypo-Fractionated Radiotherapy in Breast Cancer

This is a prospective interventional phase I/II study which will be done at Tata Medical Centre, Kolkata. Total 30 eligible female patients, ≥18 years of age, with locally advance invasive carcinoma of breast, not amenable to curative surgery of metastatic breast cancer, planned for palliative loco regional radiotherapy will be enrolled in the study amongst which patients with left sided breast cancer (at least 10) will be recruited to study the feasibility of voluntary breath hold technique for heart sparing. Once consented, all patients will have regional baseline PET-CT scan of breast and tissue biopsy along with blood sampling done before studying radiotherapy. Planning Ct scan will then be taken, with standard planning CT scan for right breast cancers with implementation voluntary breath hold technique for the left breast disease. All patients will be treated with hypo-fractionated radiotherapy with schedule of 26Gy on 5 Fractions over 1 week with 6Gy simultaneously integrated boost with incorporation of breath hold technique for left breast disease. All patients will be assessed weekly during course of radiotherapy. The toxicity will be assessed using CTCAE version 4 and LENT SOMA toxicity criteria and the impact of the hypo-fractionated breast radiotherapy schedule on quality of life in advanced incurable breast cancer patients using FACT B scores PHQ4 questionnaire will also be assessed during treatment and follow-ups tissue bio0psy will be taken after 2 hours of completion of 1 st and last fraction of radiotherapy and biobanked for future radiobiological tests. Response evaluation will be done clinically and by regional PET CT scan using PERSIST criteria in 3 months after completion of radiotherapy. After completion of treatment, patient will initially be followed up every month for 1 st three months thereby 3 monthly for 2 years and 6 monthly for next 3 years.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Sanjoy Chatterjee

Kolkata, West Bengal, 700160, India

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥18 years
  • Female
  • Invasive carcinoma of the breast
  • ECOG performance status 0-2
  • Locally advanced breast cancer which is not amenable to curative surgery as decided by multidisciplinary tumour board.
  • Metastatic breast cancer patients:
  • Who are awaiting palliative locoregional radiotherapy for symptom (pain bleeding, ulceration, impending fungation) control.
  • Who have completed a scheduled course of palliative chemotherapy and is felt to benefit from local radiation therapy
  • Able to give informed consent

Exclusion criteria

  • Breast reconstruction using implants
  • Concurrent cyto-toxic chemotherapy
  • Prior radiation to the chest wall / breast

Treatment and study plan

Hypo fractionated whole breast radiotherapy

Radiation

Hypo fractionated radiotherapy to the whole breast and SCF to a dose of 26 GY in 5 fractions with simultaneous integrated boost in advanced incurable breast cancer

Primary outcomes

  1. Toxicity (CTCAE v 4.03)

    Time frame: 3 months

    Proportion of patients with Grade 3 or more toxicity at 3 months evaluated as per the CTCAE v 4.03 criteria.

Secondary outcomes

  1. Response

    Time frame: 3 months

    To assess the response 3 months after radiotherapy clinically and by regional PET-CT scan using PERCIST criteria

Sponsors and collaborators

Lead sponsor

Tata Medical Center

Other

Registry information

Official study title

Hypo-fractionated Radiotherapy Schedule of 26 GY in 5 Fractions With Simultaneous Integrated Boost (6 GY) in Advanced Incurable Breast Cancer: A Prospective Phase I/II Study (HYPORT-B).

Acronym: HYPORT-B

Important dates

Study start
2018
Primary completion
2020
Study completion
2021
First posted
Sep 13, 2018
Registry last updated
Dec 22, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.